December 21st, 2020 | 07:50 CET
CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Pandemic creates revaluation
The Nanorepro AG share, for example, was able to profit from the "boom". While the share price was below EUR 0.50 in March 2020, a rights issue is currently underway in which existing shareholders can subscribe to new shares at a subscription price of EUR 3.03 for 3.53 old shares. The Marburg-based Company has always been a rapid diagnostics manufacturer, primarily in health planning and prevention. Nanorepro AG is one of the innovation leaders and has more than 25 rapid tests in its portfolio - including an HIV test and five other tests for specialist medical use. The Corona antibody test, which is also offered, as well as several Corona antigens tests, have now helped the Company achieve a breakthrough.
Another positive example is Formycom AG. This Company was able to report initial successes in the development of the first drug against the coronavirus. After the announcement, the share price rose from EUR 33.50 to EUR 72.00 - within four days.
European Union pays
Things can also go fast for the medical cannabis company EXMceuticals. For the "BioBlockCOVID" project, a consortium led by Portuguese subsidiary EXMceuticals Portugal Lda received a Covid-19 grant of EUR 302,000 from the European Union and the Portuguese government. The goal is to study and develop a disinfectant to combat SARS-CoV-2.
In addition to the projects around combating Corona, EXMceuticals aims to become a large-scale producer of the highest-quality cannabis ingredients for the pharmaceutical market. To this end, the Canadian-based Company has positioned itself in the European market and owns an EU-certified processing facility in Portugal to extract active ingredients from cannabis plants.
At the moment, the signs are pointing to expansion. The refinery, for example, is to be significantly expanded. After successful expansion, EXMceuticals will be able to process up to 50,000 kilograms of flowers into oil per year. According to analysts, the European cannabis market alone will grow to approximately USD 2.50 billion in the next five years, and EXMceuticals would be one of the first players in the market. The finalized plans are already with banks and authorities. If they approve the financing, the purchasing of additional machines can be initiated immediately, and worldwide sales could be accelerated. Currently, the stock market value is around CAD 11.0 million. For a European first mover in the cannabis market, there would still be room for improvement after successful approval.
Welcome to the Club
Now CureVac has made it too. The vaccine manufacturer is allowed to go into mass production of its vaccine at its site in Tübingen. The Tübingen Regional Council announced Friday that a necessary permit has now been issued. "In the current situation, supporting companies in the research and development of active substances against the coronavirus has the highest priority," Regierungspräsident Klaus Tappeser announced. "We are creating a reliable legal framework for these companies as quickly as possible while maintaining strict procedural requirements." US competitor Moderna also got the green light from the US Food and Drug Administration.
The agency gave emergency approval for the vaccine, meaning that use of the drug could begin as early as Monday. After the incumbent US President Donald Trump celebrated with the tweet "Congratulations, the Moderna vaccine is now available", the statement was revised. At first, only those in need of protection get the vaccination, for the general population it will take months until enough funds are available.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.